Trimovate
Is It Right for You?
A complete guide to Trimovate — what it treats, how it works, dosages, side effects, and when a clinician may prescribe it following an online consultation.
What Is Trimovate?
Trimovate is a triple-action topical cream that combines three active ingredients in a single yellow water-miscible formulation: clobetasone butyrate 0.05% (a moderately potent topical corticosteroid), oxytetracycline 3% (as calcium oxytetracycline — a broad-spectrum tetracycline antibiotic), and nystatin 100,000 units per gram (a polyene antifungal). This unique combination allows simultaneous treatment of three overlapping pathological processes that frequently coexist in inflamed skin: inflammation, bacterial infection, and candidal (yeast) infection.
Trimovate is particularly suited to the management of infected eczema and dermatitis affecting moist or occluded skin sites — such as flexural areas (skin folds), the groin, beneath the breasts, and intertriginous regions — where the warm, humid microenvironment predisposes to both bacterial and fungal secondary infection. It is also used in conditions such as intertrigo and napkin (nappy) rash where mixed infection is suspected or confirmed.
Trimovate is a prescription-only medication in the UK. A licensed clinician must assess the nature of the skin condition, exclude viral infection, and consider the site of application and treatment duration before prescribing.
What Conditions Is Trimovate Used For?
Trimovate is prescribed for steroid-responsive inflammatory skin conditions where bacterial or fungal infection is present, suspected, or likely to develop:
Atopic eczema, discoid eczema, contact dermatitis, and other eczematous conditions complicated by secondary bacterial or candidal infection. Clinical features suggesting infection include weeping, crusting, pustules, sudden worsening despite emollient and steroid use, and surrounding cellulitis. Trimovate's triple action addresses the underlying inflammation alongside both bacterial and fungal overgrowth in a single preparation.
Inflammation of skin folds (submammary, axillary, inguinal, abdominal) caused by friction, moisture retention, and warmth, frequently complicated by secondary candidal and bacterial colonisation. Common in patients with obesity, diabetes, and incontinence. Trimovate is well suited to intertriginous areas because it simultaneously reduces inflammation and treats the mixed infective component that perpetuates the condition.
Napkin dermatitis complicated by candidal infection — a very common combination in infants and incontinent adults. Suggested by persistent bright red rash with satellite pustules extending beyond the main area of irritation, and poor response to barrier creams alone. Trimovate should be used cautiously in this setting, for the shortest effective duration, under clinical supervision, due to the increased risk of systemic corticosteroid absorption from occluded nappy areas in infants.
Inflammatory skin conditions affecting the flexures, perianal area, and genital region where the warm, moist microenvironment predisposes to both bacterial and candidal secondary infection. Trimovate's combination of moderately potent corticosteroid with antifungal and antibacterial cover makes it particularly suitable for these sites, though use should be short-term and avoid prolonged occlusion.
Trimovate should not be used for rosacea, acne, perioral dermatitis, or itchy skin without inflammation. It is contraindicated in primary viral skin infections (including cold sores, chickenpox, and shingles) and in primary bacterial or fungal skin infections that are not steroid-responsive. Inappropriate use of topical corticosteroids on these conditions can worsen the underlying disease and cause significant adverse outcomes including skin atrophy and rebound flares.
How Does Trimovate Work?
Trimovate's three active ingredients work through complementary mechanisms to address the inflammatory and infective components of complicated skin conditions:
Clobetasone butyrate (moderately potent topical corticosteroid): Clobetasone is a synthetic glucocorticoid that binds to intracellular glucocorticoid receptors in keratinocytes and inflammatory cells. The resulting receptor-ligand complex translocates to the nucleus where it modulates gene transcription, suppressing the production of pro-inflammatory cytokines (including interleukins and tumour necrosis factor), reducing leukocyte infiltration, stabilising lysosomal membranes, and inhibiting phospholipase A2 — thereby reducing prostaglandin and leukotriene synthesis. The net effect is a marked reduction in skin inflammation, erythema, oedema, and pruritus. Clobetasone is classified as moderately potent (Group III in the UK), positioning it between mild hydrocortisone and potent agents such as betamethasone.
Oxytetracycline (broad-spectrum tetracycline antibiotic): Oxytetracycline binds reversibly to the 30S ribosomal subunit of susceptible bacteria, blocking the attachment of aminoacyl-tRNA to the ribosomal acceptor site and thereby inhibiting bacterial protein synthesis. This bacteriostatic action covers a broad range of Gram-positive and Gram-negative organisms commonly implicated in secondary skin infection, including many Staphylococcus and Streptococcus species. (Notable exceptions include MRSA, Pseudomonas, Proteus, and Serratia species, against which Trimovate is not effective.)
Nystatin (polyene antifungal): Nystatin binds to ergosterol in fungal cell membranes — particularly those of Candida species — forming pores that disrupt membrane integrity, cause leakage of intracellular contents, and lead to fungal cell death. It is highly active against Candida albicans, the principal yeast implicated in skin and mucocutaneous candidiasis, and has minimal systemic absorption when applied topically.
Dosages & Administration
The correct dose depends on the type and severity of infection, age, weight, and kidney function. Always follow your clinician's instructions. The table below is for general reference only.
Administration Tips
Apply a thin layer of Trimovate to the affected area once or twice daily, exactly as directed by your clinician. Use the smallest amount needed to cover the affected skin — overuse increases the risk of side effects without improving efficacy.
Wash and dry your hands before and after application, unless the hands are the area being treated. This reduces the risk of transferring the medication to unintended sites such as the eyes or mouth.
Avoid using Trimovate on the face, in the groin, or under occlusion (such as nappies or tight dressings) unless specifically directed by your clinician. These sites have thinner skin and increased absorption, raising the risk of skin atrophy and systemic effects.
Do not use for prolonged periods, particularly in children and infants. Extended use of topical corticosteroids can cause skin thinning, telangiectasia, striae, and — in rare cases — systemic absorption sufficient to suppress the hypothalamic-pituitary-adrenal axis.
Continue using emollients alongside Trimovate — moisturisers should be applied at a different time of day to avoid diluting the active medication. A gap of at least 30 minutes between emollient and Trimovate application is generally recommended.
Do not stop Trimovate abruptly after prolonged use. Your clinician may advise tapering the frequency of application to reduce the risk of rebound flares.
Side Effects of Trimovate
Most side effects are mild, local, and resolve on their own. Serious side effects are rare but require medical attention.
- Local skin irritation, burning, or stinging on application
- Itching or contact dermatitis
- Dryness or peeling of the treated skin
- Mild redness, particularly at initiation
- Yellow staining of skin or clothing (due to the oxytetracycline component)
- Skin atrophy (thinning), telangiectasia, and striae — risk increases with prolonged use, application to thin-skinned areas, and use under occlusion
- Hypothalamic-pituitary-adrenal axis suppression and Cushing's syndrome — rare; risk is greatest with extensive application, prolonged use, application under occlusion, and use in infants and children
- Allergic contact dermatitis — worsening of skin condition rather than improvement may indicate hypersensitivity to one of the active ingredients or excipients (including cetostearyl alcohol and chlorocresol)
- Ocular adverse effects — if Trimovate enters the eyes, it can contribute to glaucoma, cataracts, or blurred vision; rinse thoroughly if accidental exposure occurs
- Opportunistic infections — corticosteroid suppression of local immunity may allow new infections (including viral or resistant bacterial infections) to develop
- Rebound flare — abrupt discontinuation after prolonged use can cause worsening of the original skin condition
Children and infants are at substantially higher risk of systemic absorption from topical corticosteroids due to their larger surface-area-to-body-weight ratio and thinner skin. Prolonged or extensive use of Trimovate in this group — particularly under occlusion such as nappies — can lead to clinically significant adrenal suppression. Treatment in children should be at the lowest effective potency and frequency, for the shortest duration necessary, and only under clinical supervision.
Drug Interactions
Topical Trimovate has minimal potential for systemic drug interactions when used as directed. However, it is important to disclose all prescription medications, over-the-counter medicines, vitamins, and supplements to your clinician before starting treatment — particularly other topical preparations being used on the same skin areas.
Concurrent use of other topical corticosteroids on the same or nearby skin areas can compound the local and systemic adverse effects of corticosteroid therapy — including skin atrophy, telangiectasia, and (with extensive use) hypothalamic-pituitary-adrenal axis suppression. Do not combine Trimovate with another topical steroid without explicit clinical advice. Where stepwise treatment is required, your clinician will specify which preparation to use on which areas.
Extensive or prolonged topical corticosteroid use, particularly under occlusion, can result in sufficient systemic absorption to cause mild immunosuppression. In theory this could attenuate the immune response to live attenuated vaccines (such as MMR, varicella, BCG, yellow fever) and rarely permit disseminated vaccine infection. Clinical relevance is greatest in infants and children receiving Trimovate over large body areas or under nappy occlusion. Disclose recent or planned live vaccinations to your clinician before prescribing.
Concurrent application of other topical antibiotics or antifungals to the same area is unlikely to cause direct pharmacological interaction but offers no additional benefit and increases the risk of local irritation, sensitisation, and contact dermatitis. Combination antimicrobial therapy on a single skin site should be avoided unless specifically directed by your clinician.
Important Warnings
Facial skin is thin and absorbs topical corticosteroids more readily, increasing the risk of skin atrophy, telangiectasia, perioral dermatitis, and rosacea-like eruptions. Trimovate should not be applied to the face unless specifically directed by a clinician. If your clinician does prescribe it for facial use, the course should be brief and applied to the smallest possible area.
Oxytetracycline does not cover meticillin-resistant Staphylococcus aureus (MRSA), Pseudomonas species, Proteus species, Serratia species, or Streptococcus B. If a skin infection caused by any of these organisms is suspected or confirmed (for example by swab culture), Trimovate is not appropriate and an alternative antibacterial agent must be selected.
Trimovate must not be used on primary viral skin lesions including cold sores (herpes simplex), chickenpox, shingles, or molluscum contagiosum. Topical corticosteroids suppress local immune defences and can cause significant worsening or dissemination of viral infections. If a viral cause is suspected, withhold Trimovate and arrange clinical review.
Extended use of topical corticosteroids — particularly in children, on thin-skinned areas, or under occlusion (such as nappies or dressings) — can cause permanent skin thinning, telangiectasia, striae, and sufficient systemic absorption to suppress the hypothalamic-pituitary-adrenal axis. Treatment courses should be as short as possible (typically no more than 7 days), and prolonged use must only occur under direct clinical supervision with periodic review.
Trimovate is not routinely recommended in pregnancy or breastfeeding. Oxytetracycline (tetracycline class) is generally avoided in pregnancy due to effects on developing teeth and bone, although the systemic absorption from topical application is very low. Where treatment is essential in pregnancy or while breastfeeding, the smallest amount should be used for the shortest possible time and avoided around the nipple area in breastfeeding women. A clinician must weigh the benefits against the potential risks.
Speak to a Clinician About Treatment
Getting advice no longer means sitting in a waiting room. Through The GP Service, you can consult with a licensed clinician in minutes — from home, on your lunch break, or wherever works for you. If treatment is clinically appropriate, your clinician can issue a prescription during the consultation. A consultation does not guarantee a prescription.
The treatment you need, when you need it.
Trimovate FAQs
Trimovate is not recommended for use on the face. Facial skin is thinner and absorbs corticosteroids more readily, which can lead to skin thinning, telangiectasia (broken capillaries), perioral dermatitis, and rosacea-like flares. If your clinician does prescribe it for a specific facial condition, the course should be brief and applied sparingly to the smallest possible area, with close clinical review.
Trimovate is intended for short-term use, typically up to 7 days. If your skin condition has not improved by then, you should contact your clinician for review rather than continuing the cream. Prolonged use — particularly on the face, in flexures, in children, or under occlusion — increases the risk of skin atrophy and, in rare cases, systemic absorption sufficient to affect the adrenal glands.
Trimovate is generally avoided in pregnancy and breastfeeding unless clearly necessary, mainly because of the oxytetracycline component (tetracyclines are usually avoided in pregnancy due to effects on developing teeth and bone, although topical absorption is very low). If treatment is essential, your clinician will recommend the smallest effective amount for the shortest duration. If you are breastfeeding, avoid applying Trimovate to the nipple area.
If you forget to apply Trimovate at the usual time, apply it as soon as you remember unless it is nearly time for the next dose — in which case skip the missed dose and continue with your normal schedule. Do not apply a double layer to make up for the missed dose, as this does not improve efficacy and may increase the risk of side effects.
The yellow tint comes from the oxytetracycline antibiotic component and is a normal characteristic of the cream rather than a problem with the product. Skin staining washes off easily with soap and water. To minimise staining on clothing or bedding, apply Trimovate to clean dry skin, allow it to absorb fully (a few minutes), and consider wearing older clothes or covering treated areas with a light cotton dressing where practical.
Store Trimovate at room temperature, ideally below 25°C, away from direct sunlight and heat. Keep the tube tightly closed and out of the reach of children. Do not use Trimovate after the expiry date printed on the tube, and discard any opened tube after the manufacturer's recommended in-use period (typically 3 months once opened, though this can vary — check your patient information leaflet).